Axsome Therapeutics, Inc.
AXSM
Updated: 24/09/2026, 10:11:33
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
No summaries found.
- Share price
- $193.45
- Market cap
- $9.95B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Herriot Tabuteau
- Employees
- 1,346
- IPO date
- 19/11/2015
- Beta
- 0.596
- Last dividend
- $0.00
- Day range
- $189.05 – $204.70
- 52-week range
- $115.31 – $260.19
- 1-day performance
- -4.75%
- 1-year performance
- 67.77%
- Current drawdown (1Y)
- -25.65%
- CIK
- 0001579428
- CUSIP
- 05464T104
- ISIN
- US05464T1043
- Created
- 07/12/2025, 02:53:23
- Last update
- 24/09/2026, 10:11:33
Track Axsome Therapeutics, Inc. with an AI analyst
See which prediction-market events move AXSM, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Axsome Therapeutics (NASDAQ: AXSM) CEO Sells Shares Amidst Strong Stock Performance and Key Drug Developments
Market Data • Market Data • 10/06/2026, 00:13:11
Axsome Therapeutics, Inc. (AXSM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 08/06/2026, 19:58:30
Why Is Axsome (AXSM) Down 0.4% Since Last Earnings Report?
Zacks Investment Research • STOCK • 03/06/2026, 14:30:40
Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting
GlobeNewsWire • STOCK • 26/05/2026, 09:00:00
Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer's Agitation Launch
MarketBeat • STOCK • 12/05/2026, 20:08:15
Axsome Therapeutics, Inc. (AXSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 12/05/2026, 16:20:44
Axsome Therapeutics (NASDAQ:AXSM) Reports Strong Q1 Revenue Growth and Key Drug Approval Amid Insider Share Sale
Market Data • Market Data • 06/05/2026, 03:11:36
AXSM Q1 Loss Widens, Revenues Jump on Higher Auvelity Sales
Zacks Investment Research • STOCK • 05/05/2026, 15:50:29
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised Amid Strong Revenue Growth and Product Pipeline
Market Data • Market Data • 04/05/2026, 21:10:24
Axsome Therapeutics, Inc. (AXSM) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 04/05/2026, 17:43:26
Axsome Therapeutics Q1 2026 Earnings Review: Gains Mystify Me, But Can't Be Denied
Seeking Alpha • STOCK • 04/05/2026, 14:32:32
Axsome Therapeutics (AXSM) Reports Q1 Loss, Beats Revenue Estimates
Zacks Investment Research • STOCK • 04/05/2026, 11:15:27